Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H6O7.Fe |
| Molecular Weight | 245.953 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Fe++].OC(=O)C(O)(CC([O-])=O)CC([O-])=O
InChI
InChIKey=APVZWAOKZPNDNR-UHFFFAOYSA-L
InChI=1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+2/p-2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502
Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
PubMed
| Title | Date | PubMed |
|---|---|---|
| THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA. | 1937 Jul |
|
| [Ferrous lactate as an oral iron preparation for therapeutic use]. | 1954 Nov 27 |
|
| [FERROUS ASPARTATE IN THERAPY]. | 1964 Jan 1 |
|
| [Historical notes on the therapy of depression]. | 1986 Nov 22 |
|
| Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. | 2009 |
|
| Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study. | 2009 Nov 15 |
|
| The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia. | 2010 Dec |
|
| Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. | 2011 Jun 10 |
|
| A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts. | 2014 |
|
| Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
|
| Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle. | 2017 May 1 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 184.1307C
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB13864MIG
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
DTXSID701018441
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
23383-11-1
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
11064683
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
460
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
C016600
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
m5341
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
245-625-1
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
33KM3X4QQW
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
100000078449
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY | |||
|
IRON(II) CITRATE
Created by
admin on Fri Dec 15 15:11:44 GMT 2023 , Edited by admin on Fri Dec 15 15:11:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
